Please assess the completion status of the following clinical trial:

Trial Title: Prasugrel Re-load Strategies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with angiographically documented coronary artery disease.~2. Age between 18 to 74 years~3. On treatment with prasugrel 10mg/daily for at least 14 days.~Exclusion Criteria:~1. Blood dyscrasias or bleeding diathesis~2. Antiplatelet treatment with clopidogrel or ticlopidine~3. Recent antiplatelet treatment (\< 14 days) with a glycoprotein IIb/IIIa antagonist~4. Platelet count \<100x106/µL~5. Active bleeding or hemodynamic instability.~6. Unstable angina, acute or recent (\<14 days) myocardial infarction.~7. Serum creatinine \>2 mg/dL~8. Baseline ALT \>2.5 times the upper limit of normal~9. Oral anticoagulation with a coumarin derivative~10. History of stroke, TIA or intracranial bleeding~11. Weight \<60kg~12. Pregnant females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel 60mg (Type: ACTIVE_COMPARATOR): Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
- Prasugrel 30mg (Type: ACTIVE_COMPARATOR): Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
- Prasugrel 10mg (Type: NO_INTERVENTION): Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel

Based on this trial design, predict the completion outcome and termination type (if applicable).